TABLE 1.
Clinical characteristics | 1* | 2* | 3* | 4 | 5* | 6 | 7* | 8* | 9* | 10* |
---|---|---|---|---|---|---|---|---|---|---|
Diagnosis | UC | UC | UC | UC | UC | No IBD | No IBD | No IBD | No IBD | No IBD |
IBD Treatment Naïve | No | No | No | Yes | Yes | N/A | N/A | N/A | N/A | N/A |
Age at collection | 16 | 17 | 16 | 18 | 14 | 18 | 7 | 10 | 18 | 16 |
Gender | Female | Male | Female | Male | Female | Male | Male | Female | Male | Female |
Gross sigmoid disease | Yes | Yes | Yes | N/A | Yes | N/A | N/A | N/A | N/A | No |
Microscopic Sigmoid inflammation |
Yes | Yes | Yes | N/A | Yes | N/A | N/A | N/A | N/A | Yes, focal active, no chronicity |
IBD Flare (clinical) | Yes | No | Yes | N/A | Yes | N/A | N/A | N/A | N/A | N/A |
Paris Disease Location (UC)a | E1 | E4 | E2 | N/A | E3 | N/A | N/A | N/A | N/A | N/A |
UC Paris Disease severityb | S0 | S1 | S0 | N/A | S1 | N/A | N/A | N/A | N/A | N/A |
Paris Age at IBD Diagnosisc | A1a | A2 | A1b | N/A | A1b | N/A | N/A | N/A | N/A | N/A |
IBD Medications | Mesalamine, prednisone |
Prednisone, mesalamine, metronidazole |
Mesalamine, balsalazide |
None | None | N/A | N/A | N/A | N/A | N/A |
PUCAId (on day of collection) | 30, PUCAI | 0, PUCAI | 35, PUCAI | N/A | 70, PUCAI | N/A | N/A | N/A | N/A | N/A |
E1 - Ulcerative proctitis, E2 - Left sided (distal to splenic flexure), E3 - Extensive (hepatic flexure distally), E4 - Pancolitis (proximal to hepatic fixture), N/A: Not available or not applicable (if no IBD)
S0: never severe, S1: ever severe (PUCAI > or = 65 ever), N/A: Not available or Not applicable (if no IBD)
A1a: 0–9 years old (yo), A1b: 10–16 yo, A2: >16 yo, N/A = Not available or Not applicable (if no IBD)
Pediatric Ulcerative Colitis Activity Index
Samples used for subsequent validation by rt-PCR